Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Endocrine 1

Conditions

Colorectal Neoplasms 3Cholangiocarcinoma 2Rectal Neoplasms 1Neoplasm Metastasis 1Colonic Neoplasms 1Cirrhosis, Familial, with Pulmonary Hypertension 1Bile Duct Neoplasms 1Adrenocortical Carcinoma 1Adrenal Gland Neoplasms 1Adrenal Cortex Neoplasms 1

Interventions

Gemcitabine 6Cisplatin 6pembrolizumab 3durvalumab 3Oxaliplatin 3tivozanib 2Specimen Handling 2Magnetic Resonance Spectroscopy 2trametinib 1tislelizumab 1olaparib 1atezolizumab 1Yttrium-90 1Stents 1Radiosurgery 1Nivolumab 1Leucovorin 1Ipilimumab 1Folfox protocol 1Fluorouracil 1Floxuridine 1Dexamethasone 1Capecitabine 1CTLA-4 Antigen 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bile Duct Neoplasms × Floxuridine × 90 days × Clear all
NCT05286814 2026-05-04

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
70 enrolled
EndocrineGastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Bile Duct Neoplasms, Colorectal Neoplasms, Adrenocortical Carcinoma, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡